LIKMEZ Drug Patent Profile
✉ Email this page to a colleague
When do Likmez patents expire, and what generic alternatives are available?
Likmez is a drug marketed by Saptalis Pharms and is included in one NDA. There is one patent protecting this drug.
This drug has five patent family members in five countries.
The generic ingredient in LIKMEZ is metronidazole. There are eighteen drug master file entries for this compound. Seventy-three suppliers are listed for this compound. Additional details are available on the metronidazole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Likmez
A generic version of LIKMEZ was approved as metronidazole by TEVA PHARMS USA on November 6th, 1984.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LIKMEZ?
- What are the global sales for LIKMEZ?
- What is Average Wholesale Price for LIKMEZ?
Summary for LIKMEZ
International Patents: | 5 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Drug Prices: | Drug price information for LIKMEZ |
What excipients (inactive ingredients) are in LIKMEZ? | LIKMEZ excipients list |
DailyMed Link: | LIKMEZ at DailyMed |
Pharmacology for LIKMEZ
Drug Class | Nitroimidazole Antimicrobial |
US Patents and Regulatory Information for LIKMEZ
LIKMEZ is protected by one US patents.
Patents protecting LIKMEZ
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Saptalis Pharms | LIKMEZ | metronidazole | SUSPENSION;ORAL | 216755-001 | Sep 22, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LIKMEZ
See the table below for patents covering LIKMEZ around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Brazil | 112020014376 | composição farmacêutica oral, e, método para tratar uma infecção em um paciente. | ⤷ Sign Up |
Mexico | 2020007494 | FORMULACIONES ORALES DE METRONIDAZOL Y METODOS DE TRATAMIENTO DE UNA INFECCION CON LAS MISMAS. (ORAL FORMULATIONS OF METRONIDAZOLE AND METHODS OF TREATING AN INFECTION USING SAME.) | ⤷ Sign Up |
European Patent Office | 3768321 | FORMULATIONS ORALES DE MÉTRONIDAZOLE ET MÉTHODES DE TRAITEMENT D'UNE INFECTION FAISANT APPEL À CELLES-CI (ORAL FORMULATIONS OF METRONIDAZOLE AND METHODS OF TREATING AN INFECTION USING SAME) | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2019140516 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LIKMEZ
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0328535 | 96C0021 | Belgium | ⤷ Sign Up | PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |